| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 98,897 | 247,970 | ||
| Accounts receivable, net of allowance for credit loss of nil | 8,323 | 2,693 | ||
| Inventory | 5,710 | 552 | ||
| Prepaid expenses and other current assets | 8,925 | 8,257 | ||
| Marketable securities | 450,148 | 359,752 | ||
| Interest receivable on marketable securities | 5,527 | 3,984 | ||
| Total current assets | 577,530 | 623,208 | ||
| Property and equipment, net of accumulated depreciation of 1,110 and 874, respectively | 560 | 615 | ||
| Intangible assets, net of accumulated amortization of 1,390 and 448, respectively | 11,680 | 12,145 | ||
| Operating lease right-of-use assets | 4,329 | 4,641 | ||
| Other non-current assets | 7,462 | 6,616 | ||
| Total assets | 601,561 | 647,225 | ||
| Accounts payable | 15,360 | 22,419 | ||
| Current operating lease liabilities | 1,871 | 1,808 | ||
| Contract liabilities, current portion | 6,721 | 9,725 | ||
| Liability related to revenue interest financing agreement | 5,982 | 2,823 | ||
| Short-term borrowings | 5,618 | 5,583 | ||
| Accrued expenses | 32,579 | 23,998 | ||
| Total current liabilities | 68,131 | 66,356 | ||
| Warrant liability | 1,738 | 2,350 | ||
| Contract liabilities, net of current portion | 11,130 | 12,459 | ||
| Non-current operating lease liabilities | 2,970 | 3,399 | ||
| Non-current liability related to revenue interest financing agreement, net of current portion and deferred financing costs of 4,450 and 0 as of september 30, 2025 and december 31, 2024 | 144,621 | 142,780 | ||
| Long-term borrowings, net of current portion and deferred financing costs of 3,161 and 0 as of september 30, 2025 and december 31, 2024 | 47,089 | 46,974 | ||
| Total liabilities | 275,679 | 274,318 | ||
| Class a and class b common stock and additional paid in capital, 0.0001 par value per share 1,060,000,000 (class a 1,000,000,000, class b 60,000,000) shares authorized as of september 30, 2025 and december 31, 2024 respectively, 342,752,387 (class a 341,755,387, class b 1,000,000) and 337,837,872 (class a 336,837,872, class b 1,000,000) shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 1,404,799 | 1,396,220 | ||
| Accumulated deficit | -1,078,778 | -1,022,986 | ||
| Accumulated other comprehensive (loss) income | -139 | -327 | ||
| Total stockholders' equity | 325,882 | 372,907 | ||
| Total liabilities and stockholders' equity | 601,561 | 647,225 | ||
Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc. (NUVB)